Floatz logo

Iparomlimab

ES-SCLC

Sun Yat-sen UniversityPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the ES-SCLC cohort.

Asset / SponsorPhaseRating
Tuvonralimab
The Second Affiliated Hospital of Dalian Medical University
Phase 3BB

Same molecule, other indications

Iparomlimab is also rated in:

HCC - Hepatocellular CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →
BevacizumabDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →